Iovance Biotherapeutics (IOVA) Competitors $1.78 +0.04 (+2.01%) As of 12:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IOVA vs. IBRX, XENE, BHC, GMTX, APLS, ARWR, TWST, VCEL, KNSA, and NAMSShould you be buying Iovance Biotherapeutics stock or one of its competitors? The main competitors of Iovance Biotherapeutics include ImmunityBio (IBRX), Xenon Pharmaceuticals (XENE), Bausch Health Cos (BHC), Gemini Therapeutics (GMTX), Apellis Pharmaceuticals (APLS), Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Vericel (VCEL), Kiniksa Pharmaceuticals International (KNSA), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry. Iovance Biotherapeutics vs. Its Competitors ImmunityBio Xenon Pharmaceuticals Bausch Health Cos Gemini Therapeutics Apellis Pharmaceuticals Arrowhead Pharmaceuticals Twist Bioscience Vericel Kiniksa Pharmaceuticals International NewAmsterdam Pharma ImmunityBio (NASDAQ:IBRX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk. Does the media refer more to IBRX or IOVA? In the previous week, Iovance Biotherapeutics had 35 more articles in the media than ImmunityBio. MarketBeat recorded 37 mentions for Iovance Biotherapeutics and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.28 beat Iovance Biotherapeutics' score of 0.18 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Iovance Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 29 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts recommend IBRX or IOVA? ImmunityBio currently has a consensus target price of $12.25, suggesting a potential upside of 356.24%. Iovance Biotherapeutics has a consensus target price of $12.22, suggesting a potential upside of 584.72%. Given Iovance Biotherapeutics' higher possible upside, analysts clearly believe Iovance Biotherapeutics is more favorable than ImmunityBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Iovance Biotherapeutics 0 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation and earnings, IBRX or IOVA? Iovance Biotherapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunityBio$14.74M160.78-$413.56M-$0.58-4.63Iovance Biotherapeutics$164.07M3.63-$372.18M-$1.24-1.44 Is IBRX or IOVA more profitable? Iovance Biotherapeutics has a net margin of -176.49% compared to ImmunityBio's net margin of -1,310.30%. ImmunityBio's return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmunityBio-1,310.30% N/A -121.88% Iovance Biotherapeutics -176.49%-49.71%-39.18% Which has more risk and volatility, IBRX or IOVA? ImmunityBio has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500. Comparatively, Iovance Biotherapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Do insiders and institutionals have more ownership in IBRX or IOVA? 8.6% of ImmunityBio shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 76.8% of ImmunityBio shares are owned by insiders. Comparatively, 10.3% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryIovance Biotherapeutics beats ImmunityBio on 10 of the 17 factors compared between the two stocks. Get Iovance Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IOVA vs. The Competition Export to ExcelMetricIovance BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$596.07M$2.89B$5.49B$8.92BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-1.4421.3826.2019.83Price / Sales3.63277.62404.03113.43Price / CashN/A41.8936.4957.06Price / Book0.777.347.985.35Net Income-$372.18M-$55.05M$3.15B$248.34M7 Day Performance0.28%1.69%1.48%2.40%1 Month Performance1.42%6.28%4.33%5.39%1 Year Performance-76.91%4.67%35.36%19.53% Iovance Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IOVAIovance Biotherapeutics4.6992 of 5 stars$1.78+2.0%$12.22+588.6%-78.4%$592.73M$164.07M-1.43500IBRXImmunityBio2.0562 of 5 stars$2.77-3.7%$12.25+343.0%-59.0%$2.44B$14.74M-4.77590Gap DownXENEXenon Pharmaceuticals3.1313 of 5 stars$31.54-1.6%$54.82+73.8%-14.9%$2.42B$9.43M-9.76210BHCBausch Health Cos3.233 of 5 stars$6.12-1.1%$7.42+21.3%-4.4%$2.26B$9.73B-55.5920,700GMTXGemini TherapeuticsN/A$51.61+3.0%N/A+17.5%$2.24BN/A-51.6130High Trading VolumeAPLSApellis Pharmaceuticals4.5752 of 5 stars$17.63-0.3%$40.05+127.1%-50.8%$2.22B$775.84M-9.85770News CoverageAnalyst RevisionARWRArrowhead Pharmaceuticals3.9181 of 5 stars$15.51+1.2%$43.71+181.9%-38.2%$2.14B$3.55M-11.08400Positive NewsTWSTTwist Bioscience4.3357 of 5 stars$35.26+1.8%$50.40+42.9%-24.9%$2.11B$347.68M-10.85990News CoverageVCELVericel2.9078 of 5 stars$41.65-0.9%$61.14+46.8%-7.6%$2.10B$237.22M1,388.76300Positive NewsKNSAKiniksa Pharmaceuticals International3.553 of 5 stars$28.72+1.0%$38.80+35.1%+51.3%$2.10B$423.24M-114.88220NAMSNewAmsterdam Pharma2.8934 of 5 stars$18.23+1.5%$42.89+135.3%-11.5%$2.05B$45.56M-9.704 Related Companies and Tools Related Companies ImmunityBio Competitors Xenon Pharmaceuticals Competitors Bausch Health Cos Competitors Gemini Therapeutics Competitors Apellis Pharmaceuticals Competitors Arrowhead Pharmaceuticals Competitors Twist Bioscience Competitors Vericel Competitors Kiniksa Pharmaceuticals International Competitors NewAmsterdam Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IOVA) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IOVA Stock Alerts